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ABSTRACT 
 
Objective. The ZNF804A gene and cannabis use are risk factors for psychosis, both of which have 
also been associated with schizotypic traits. This study aimed to test whether ZNF804A (rs1344706) 
modulates the relation between cannabis use and schizotypy levels in a general population sample. 
 
Method. The sample consisted of 389 Spanish non-clinical subjects (43% males, mean 
age=21.1(2.19)). Schizotypy was evaluated with the three factors of the Schizotypal Personality 
Questionnaire-Brief (SPQ-B): Cognitive-Perceptual (CP), Interpersonal (I) and Disorganized (D). 
Subjects were classified as cannabis users or non-users. Multiple linear regressions were conducted 
to test the effect of genetic and environment factors and their interaction on SPQ-B scores. Sex and 
anxiety scores (evaluated with SCL) were included as covariates.  
 
Results. The analyses showed a significant linear relationship between the ZNF804A and SPQ-I: 
homozygotes AA showed higher scores (p=0.001). An interaction between cannabis use and 
rs1344706 on SPQ-CP was observed: among individuals AA, cannabis users presented higher 
scores than non-users, while among individuals CC, cannabis users presented lower scores 
compared to non-users (p=0.005). 
 
Conclusion. These results add evidence on that the ZNF804A modulates schizotypy and suggest 
that schizotypy levels are influenced by an interaction between the exposure to cannabis and the 
ZNF804A genotype.  
 
Keywords: ZNF804A, cannabis, psychosis, schizotypy, gene-environment interaction  
 
Significant outcomes: 
- Our study supports the notion that the gene ZNF804A has an effect on a psychosis vulnerability 
marker such as schizotypy in healthy individuals. 
- The association between cannabis use and schizotypy is modulated by the ZNF804A gene. 
 
 
Limitations: 
- Cross-sectional design and self-referred measures of schizotypy and cannabis use may 
constitute an inherent source of bias.  
- Non-existent previous studies testing ZNF804Axcannabis interaction, the sample size and the 
non-availability of a replication sample make necessary further studies to confirm the results. 
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1. Introduction 
Psychotic disorders, including schizophrenia (SZ), are among the most severe and 
impairing conditions, with lifetime prevalence around 3% (1). Psychotic disorders are 
multifactorial disorders determined by genetic, environmental risk factors and the 
interaction between these factors (2,3).  
As regards to genetic factors, twin and family studies have estimated that the 
heritability of SZ is between 64% and 81% (4,5). Moreover, genome-wide association 
studies (GWAS) have reported a substantial polygenic component that contributes to 
the risk for these disorders (6,7). These studies have allowed identifying several new 
candidate gens for SZ and one of the most relevant is the ZNF804A gene. 
Subsequently, this association has been further explored and replicated, which has 
enhanced the understanding of its involvement in SZ (7–11). 
ZNF804A (2q32.1) is expressed throughout the foetal and adult human brain, 
especially in the medial temporal lobe and brain cortices (12,13). Despite the exact 
functions of ZNF804A still remains unclear, proteins with zinc finger domains are 
known to play a variety of roles, including binding to DNA, transcriptional regulation, 
gene expression and DNA–protein interactions (11,14,15). In this regard, molecular 
and bioinformatic studies suggest that ZNF804A likely has pivotal roles in cell 
physiology by its involvement in neurodevelopment regulation (8), synaptic plasticity 
(16) and also with brain structure and function (12,17). More specifically, ZNF804A 
has been reported to be involved in early neurite outgrowth and in regulating spine 
maintenance and the ability of neurons to respond to activity-dependent stimuli (16). 
As a putative transcription factor, ZNF804A has a large number of potential targets 
both in the developing foetus and the adult brain, including genes that are involved in 
neuronal migration, neurite outgrowth and synaptic transmission (18). Interestingly, 
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some of the genes regulated by ZNF804A, such as the Dopamine Receptor D2 
(DRD2) or Catechol-O-Methyltransferase (COMT), are directly involved in 
dopaminergic transmission and have been associated with schizophrenia (19). 
Therefore, current evidence suggests that dysregulation of ZNF804A could contribute 
to the altered neuronal and synaptic structures that are associated with psychotic and 
other neurodevelopmental disorders (20).  
Within ZNF804A gene, the rs1344706 single-nucleotide polymorphism (SNP) has 
been repeatedly associated with psychosis (6,9,10,21) and the A variant has been 
identified with an increased risk for these disorders. In addition, two independent 
studies have shown that the risk allele of rs1344706 is associated with reduced 
expression of ZNF804A RNA, both in brain tissue of foetus and in individuals with 
schizophrenia, bipolar disorder or major depression disorder(12,13). 
Two studies have also associated the rs1344706 with a vulnerability marker for 
psychosis, such as schizotypy (22,23). Schizotypy is a set of personality traits 
encompassing behaviours, cognitions and emotions that resemble the signs and 
symptoms of psychotic disorders in the general population. Schizotypy encompasses 
perceptual impairments and unusual views or ideas, a loss of normal emotional, 
physical and social functions and odd behaviour and speech, among other traits(24). 
Due to the clinical resemblance between schizotypy and psychotic symptoms it has 
been suggested that overlapping aetiological factors might underlie the two 
phenotypes (25). Therefore the study of the genetic underpinnings of vulnerability traits 
in non-clinical samples constitutes a useful framework within which to investigate 
aetiological factors of psychotic disorders (26).  
One of the environmental risk factors most strongly implicated with the emergence of 
psychotic symptoms and disorders is the use of cannabis (27,28). Cannabis can induce 
psychotic symptoms through the activation of the endocannabinoid system, which is an 
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endogenous system that modulates dopamine neurotransmission (29). Interestingly, 
cannabis use has also been associated with schizotypy, being the positive and the 
disorganized dimensions of schizotypy the most strongly related (30–33). However, only 
a relatively small proportion of cannabis users develop psychotic symptoms, which 
means that other factors might explain the interaction between cannabis and psychosis 
risk (34). In this context, epidemiological studies have found that the risk for psychosis 
associated with cannabis use is increased in individuals with genetic vulnerability to 
psychosis (positive family history) (35). Similarly, familial correlation of schizotypal 
scores varies depending on the exposure to cannabis, which confirms the importance 
of gene-cannabis interaction in the expression of psychosis vulnerability markers 
(36,37). 
As regard to gene-cannabis interaction, some studies have shown the interaction 
between dopaminergic neurotransmission related genes (COMT and AKT1) and 
cannabis use on psychosis risk (35). Taking into consideration these previous studies, 
and the regulatory roles of ZNF804Aboth neurodevelopmental processes and gene 
expression, it is therefore of interest to study the interaction between ZNF804A and 
cannabis use in order to increase the knowledge of the underlying mechanism by which 
cannabis increases the risk for psychosis. Despite that both ZNF804A gene and 
cannabis use have been independently described as genetic and environmental risk 
factors not only for psychosis but also for a psychotic vulnerability marker such as 
schizotypy, there are no studies assessing the GxE between ZNF804A gene and the 
cannabis use in psychosis.  
Therefore, this study aimed to investigate the impact of cannabis use on schizotypal 
personality traits conditional to the genetic variability at ZNF804Agene in a general 
population sample. We hypothesized that the SNP rs1344706 within the ZNF804Agene 
would modulate the relationship between a well known environmental risk factor for 
psychotic disorders such as cannabis and the schizotypy levels in adult healthy subjects. 
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2. Method 
2.1. Sample 
The sample consisted of 389 subjects from the Spanish general population who were 
recruited in 2004-05 at the campus of the Jaume I University in Castelló (Spain).  
Exclusion criteria were the presence of any major medical illness affecting brain function, 
neurological conditions, and personal history of head injury or psychiatric medical 
treatment. These areas were screened by trained psychologists by using a short 
interview designed for this study that included selected items of psychiatric diagnosis 
structured scales such as Structured Clinical Interview for DSM-IV (SCID-I) (38) and 
Familiar Interview for Genetic Studies (FIGS) (39). Specific questions about psychiatric 
assistance, psychotropic medication, hospital admissions and suicide attempts were 
asked to the participants.  
Ethical approval was obtained from local research ethics committees. All participants 
provided written consent after being informed about the study procedures and 
implications. All procedures were carried out according to the Declaration of Helsinki. 
 
2.2. Measures 
The schizotypal personality was measured with Schizotypal Personality Questionnaire-
Brief (SPQ-B) (40). The SPQ-B consists of 22-items self-report scale and comprises 
three identifiable factors (cognitive-perceptual (CP), interpersonal (I) and disorganized 
(D)). The CP and the I factors included 8 items each one and the D factor 6 items, and 
the final score of each factor was calculated as the sum of all the items of each factor. 
These factors include the evaluation of the presence of odd ideas, paranoia, lack of close 
personal relationship, suspiciousness and odd behaviour and speech. The participants 
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were screened for their anxious symptomatology by means of the 23-item scale of the 
revised version of the Symptom Check List, SCL-90-R (41). Clinical information was 
available for 100% of individuals. 
 
Life-time cannabis use was assessed with one question regarding the frequency of 
consumption “never”, “sometimes”, “monthly”, “weekly” or “daily”. This variable was then 
dichotomized in: cannabis use (daily, weekly, and monthly) or non-cannabis use 
(sometimes or never). This information was available for 98.9% of individuals. 
Similarly, participants were asked about the use of other illicit drugs (i.e. amphetamine- 
type stimulants, cocaine, heroin and other opioids, or ecstasy) and were classified as 
other drugs users (daily, weekly, and monthly) or other drugs non-users  (occasionally 
or never).  
 
2.3. Molecular analyses 
 
Genomic DNA from each individual was extracted from buccal mucosa samples by 
means of a cotton swab using the BuccalAmp DNA (Epicentre® Biotechnologies, 
Madison, WI). The SNP (rs1344706) atZNF804A gene was determined using Applied 
Biosystems TaqMan 5’ exonuclease assays. Polymerase chain reaction plates were 
read on ABI PISM 7900HT instrument with SDS 2.4 software (Applied Biosystems). The 
genotyping call rate for the SNP was 100%. 
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2.4. Statistical analyses 
 
All data were processed using PASW statistics (SPSS Inc., Chicago Illinois, USA) and 
Stata v. 14 (StataCorp, 2013). 
 
The Student’s t test and ANOVA test were used to compare the means of continuous 
variables between two or more groups, respectively. Chi-squared test were performed 
to analyze the distribution of qualitative variables between groups.  
 
Multiple linear regressions were conducted to test the effect of genetic and environment 
factors and their interaction on SPQ-B scores. First, the main effect of the independent 
variables (rs1344706 and cannabis use) was tested in the same model on each SPQ 
dimension (SPQ-CP, SPQ-I, SPQ-D). Second, the interaction between rs1344706 and 
cannabis use on each SPQ-dimension was analyzed. Sex, SCL anxiety scores and the 
use of other drugs were included as covariates.  
The presence of Hardy-Weinberg equilibrium was examined using the chi-squared test 
with PLINK v1.07 (42). 
 
Considering that three models were tested (effect of cannabis and genotype on the three 
SPQ dimensions), significant p-value threshold was established at 0.017 (0.05/3). 
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3. Results 
 
3.1 Sample description 
Participants (n=389) were university students (43% males) with a mean age at interview 
of 21.11 years (sd=2.19). The SPQ-Band SCL-anxiety mean scores (sd) were as follows: 
SPQ-CP 1.57(1.49), SPQ-I 2.76(2.12), SPQ-D 1.15(1.23) and SCL-A 4.20(4.99). 
The 29% of individuals were classified as cannabis users and 12% of individuals were 
classified as other drugs users. 
The genotypic frequencies were in Hardy-Weinberg equilibrium and allelic frequencies 
were similar to those described for European population in 1000 Genomes Project 
(MAF=38%). The genotypic frequencies were as follows: 31.2% AA, 47.0% AC and 
21.8% CC. 
There were no statistically significant differences between cannabis users and non-users 
on age, genotype, SCL scores and the SPQ-CP and SPQ-I. However, there were 
significant differences on sex (60% of the cannabis non-users were females (χ²=5.8 
p=0.016)) and SPQ-D (cannabis users had higher SPQ-D scores than non-users (t=-
2.38 p=0.017 R2=0.21)). 
 
3.2 Effects of cannabis use and ZNF804A genotype on SPQ-B 
Regarding the Interpersonal schizotypy factor, a significant linear relationship between 
the genotype and the schizotypal scores was observed: homozygotes AA showed higher 
Interpersonal schizotypal scores (β=-0.16 SE=0.14 p=0.001 R2=0.13). The mean (sd) 
SPQ-I scores for each genotype were as follow: AA (3.19 (0.19)), AC (2.65 (0.15)) and 
CC (2.36 (0.22)). No effect of cannabis use nor the interaction between genotype x 
cannabis was detected on SPQ-I. 
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In reference to the Cognitive-Perceptual factor, no effect of the main factors (genotype 
and cannabis) was observed. However, the interaction analysis showed the interplay 
between cannabis use and rs1344706 on SPQ-CP (β=0.21 SE=0.44 p=0.005 R2=0.19): 
depending on the ZNF804A genotype the exposure to cannabis is associated differently 
to Cognitive Perceptual schizotypal scores (Figure 1). Heterozygous individuals showed 
similar SPQ-CP scores regardless of their cannabis use, while in the two homozygous 
groups (AA or CC) the cannabis use showed contrary effects. Among individuals AA, 
cannabis users presented higher scores than non-users, while among CC cannabis 
users presented lower scores compared to non-users. 
In order to better detail the interaction analysis, we tested the effect of the genotype on 
SPQ-CP score separately in the group of cannabis users and non-users. Linear 
regression analyses showed that there is a significant effect of the genotype on SPQ-CP 
only in the group of cannabis users (β=-0.20 SE=0.20 p=0.025 R2=0.04). Then, within 
cannabis users group, AA homozygotes have the highest SPQ-CP ratings while within 
cannabis non-users there are no significant differences among genotypic groups. 
 
Finally, no significant effect of the genotype, cannabis use or the interaction was 
observed on SPQ-D. 
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Figure 1. Among cannabis users, individuals AA showed higher scores in SPQ-CP 
(SD) dimensions than CC, while non-users showed the opposite trend (AA lower 
scores than CC). n= number of individuals.  
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4. Discussion 
 
This study adds evidence on that ZNF804A gene may exert certain effect on psychosis 
proneness, measured as schizotypal traits in healthy subjects. In addition, our findings 
suggest, for the first time, that genetic variability at the ZNF804A gene may modulate the 
relationship between the cannabis use and psychotic proneness. 
 
On the one hand, we have observed an association between the rs1344706 with SPQ-
I. Particularly, we found that homozygotes AA showed higher Interpersonal schizotypal 
scores. This result is in line with different studies reporting the association of this variant 
with schizophrenia risk (e.g., 6,10), and it is also consistent with two previous studies 
that found this variant associated with schizotypy in general population sample (22,23). 
In regard to the two prior non-clinical population based studies, Yasuda et al. (2011) 
reported that A carriers showed higher disorganization dimension, but they did not 
describe differences in the other schizotypal factors. In the second study, although the 
direction of association was opposed to what expected, Stefanis et al. (2013) reported 
an association between paranoid and disorganized dimensions and rs1344706. 
Differences in the results among our study and the two previous studies might be 
explained by different sample characteristics, such as differences in sample size, ethnic 
origin or age and sex distributions. For instance, Yasuda’s study consisted of 176 
Japanese individuals with a mean age of 36.8 (sd=11.5) years. In Stefanis’ study, 
although the subject’s mean age (21 years, sd=1.9) was similar to our study, 100% of 
the subjects were men undergoing military service. Despite these differences, our results 
add onto the body of evidence that the ZNF804A gene might be involved in the 
pathogenesis of schizophrenia. 
On the other hand, we have not observed an effect of cannabis use per se and either of 
the genotype on schizotypy ratings. However, the GxE interaction analyses have shown 
that the cannabis use seems to act as a modifier of the association between the 
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rs1344706 genotype and Cognitive Perceptual schizotypal scores. Among cannabis 
users, individuals AA showed higher scores in SPQ-CP dimensions than CC, while non-
users showed the opposite trend. As observed when the effect of the genotype on SPQ-
CP score was tested separately in the group of cannabis users and non-users, the 
rs1344706 genotype is linearly related with SPQ-CP scores only in the group of cannabis 
users. 
 
For the interpretation of this GxE interplay, it is essential to understand the biological 
function of ZNF804A gene and the effect of a polymorphic variant in it. As mentioned, 
ZNF804A is presumably involved in the development and function of neural and synaptic 
structures (43), that regulates the expression of other genes, some of which have been 
directly or indirectly previously associated with schizophrenia (19,44). 
To this respect, it was first considered whether the risk allele affects the expression of 
ZNF804A or even other genes. Two studies converge in showing that the SNP 
rs1344706 has a cis-acting effect on ZNF804A expression in the human foetal brain 
(12,13), a critical period in neurodevelopment. Specifically, these studies showed 
reduced expression associated with the risk allele; however, allelic direction still remains 
controversial due to contradictory results from other studies (45,46). Nonetheless, it can 
be hypothesized that the dysregulation of ZNF804A expression could have an effect on 
important neurodevelopmental processes that ultimately might increase the risk to 
develop psychosis in adolescence. However, since rs1344706 maps to an intronic 
region, the mechanisms causing these expression changes remains poorly understood. 
In this sense, a recent study suggested that the MYT1L and GATA2 genes, which are 
involved in oligodendrocyte and neuronal differentiation and have been previously 
associated with schizophrenia, are strong candidates for regulating ZNF804A expression 
via rs1344706 (47).  However, further effort is needed in determining the proteins that 
interact with the rs1344706 motif in order to elucidate the mechanism by which this SNP 
affects the ZNF804A expression.  
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Some limitations of this study must be acknowledged. First, the cross-sectional design 
is not the optimal to test causal associations and the retrospective measures may 
constitute an inherent source of bias. However, the genetic and environmental variables 
were selected based on previous findings and the analyses had a directional hypothesis 
also defined according to evidence (48,49). Second, participants were self-referred for 
the study, which may have introduced a selection bias into our sample. Despite these 
limitations, we would like to outline the design of this study as an intrinsic strength, 
because the assessment of the association between cannabis use and schizotypy aims 
to overcome the presence of multiple confounding factors inherent to psychosis; such as 
medication or the heterogeneous symptomatology of the disorder. 
Further analyses in independent samples are required to replicate the present results 
and also to improve the knowledge of the etiological mechanism underlying the risk for 
psychosis, both in general population and in clinical samples. 
 
In conclusion, our study supports the notion that the gene ZNF804A has an effect on a 
psychosis vulnerability marker such as schizotypy in healthy individuals from the 
population, and shows for the first time that this effect can be modulated by cannabis 
use.  
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